Vistagen Therapeutics Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Public

  • Employees
  • 57

Employees

  • Stock Symbol
  • VTGN

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $2.06
  • (As of Friday Closing)

Vistagen Therapeutics General Information

Description

Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 343 Allerton Avenue
  • South San Francisco, CA 94080
  • United States
+1 (650)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 343 Allerton Avenue
  • South San Francisco, CA 94080
  • United States
+1 (650)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vistagen Therapeutics Stock Performance

As of 20-Jun-2025, Vistagen Therapeutics’s stock price is $2.06. Its current market cap is $59.9M with 29.2M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.06 $2.06 $1.90 - $4.21 $59.9M 29.2M 144K -$1.67

Vistagen Therapeutics Financials Summary

As of 31-Mar-2025, Vistagen Therapeutics has a trailing 12-month revenue of $486K.

In Thousands,
USD
TTM 31-Mar-2025 FY 2025 31-Mar-2025 FY 2024 31-Mar-2024 FY 2023 31-Mar-2023
EV (14,692) (14,692) 18,389 5,459
Revenue 486 486 1,064 (227)
EBITDA (55,333) (55,333) (32,141) (58,736)
Net Income (51,418) (51,418) (29,362) (59,248)
Total Assets 84,341 84,341 123,653 21,089
Total Debt 1,509 1,509 2,120 2,711
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Vistagen Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Vistagen Therapeutics‘s full profile, request access.

Request a free trial

Vistagen Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicat
Biotechnology
South San Francisco, CA
57 As of 2025

New York, NY
 

Coral Gables, FL
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Vistagen Therapeutics Competitors (10)

One of Vistagen Therapeutics’s 10 competitors is Axsome Therapeutics, a Corporation company based in New York, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Axsome Therapeutics Corporation New York, NY
Relmada Therapeutics Formerly VC-backed Coral Gables, FL
Intracellular Therapies Formerly VC-backed Bedminster, NJ
Merck & Co. Corporation Rahway, NJ
Aptinyx Formerly VC-backed Evanston, IL
You’re viewing 5 of 10 competitors. Get the full list »

Vistagen Therapeutics Patents

Vistagen Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021277216-A1 Treatment of adjustment disorders Inactive 18-May-2020
EP-4153182-A1 Treatment of adjustment disorders Pending 18-May-2020
CA-3178758-A1 Treatment of adjustment disorders Pending 18-May-2020
US-20230210867-A1 Treatment of adjustment disorders Pending 18-May-2020
EP-4153182-A4 Treatment of adjustment disorders Pending 18-May-2020 A61K31/568
To view Vistagen Therapeutics’s complete patent history, request access »

Vistagen Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vistagen Therapeutics Acquisitions (3)

Vistagen Therapeutics’s most recent deal was a Merger/Acquisition with Pherin Pharmaceuticals for . The deal was made on 02-Feb-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Pherin Pharmaceuticals 02-Feb-2023 Merger/Acquisition Drug Discovery
Excaliber Enterprises 11-May-2011 Merger/Acquisition Distributors/Wholesale
Artemis Neuroscience 19-Nov-2003 Merger/Acquisition Pharmaceuticals
To view Vistagen Therapeutics’s complete acquisitions history, request access »

Vistagen Therapeutics ESG

Risk Overview

Risk Rating

Updated April, 25, 2023

27.15 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,842

Rank

Percentile

Pharmaceuticals

Industry

of 898

Rank

Percentile

Biotechnology

Subindustry

of 402

Rank

Percentile

To view Vistagen Therapeutics’s complete esg history, request access »

Vistagen Therapeutics FAQs

  • When was Vistagen Therapeutics founded?

    Vistagen Therapeutics was founded in 1998.

  • Where is Vistagen Therapeutics headquartered?

    Vistagen Therapeutics is headquartered in South San Francisco, CA.

  • What is the size of Vistagen Therapeutics?

    Vistagen Therapeutics has 57 total employees.

  • What industry is Vistagen Therapeutics in?

    Vistagen Therapeutics’s primary industry is Biotechnology.

  • Is Vistagen Therapeutics a private or public company?

    Vistagen Therapeutics is a Public company.

  • What is Vistagen Therapeutics’s stock symbol?

    The ticker symbol for Vistagen Therapeutics is VTGN.

  • What is the current stock price of Vistagen Therapeutics?

    As of 20-Jun-2025 the stock price of Vistagen Therapeutics is $2.06.

  • What is the current market cap of Vistagen Therapeutics?

    The current market capitalization of Vistagen Therapeutics is $59.9M.

  • What is Vistagen Therapeutics’s current revenue?

    The trailing twelve month revenue for Vistagen Therapeutics is $486K.

  • Who are Vistagen Therapeutics’s competitors?

    Axsome Therapeutics, Relmada Therapeutics, Intracellular Therapies, Merck & Co., and Aptinyx are some of the 10 competitors of Vistagen Therapeutics.

  • What is Vistagen Therapeutics’s annual earnings per share (EPS)?

    Vistagen Therapeutics’s EPS for 12 months was -$1.67.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »